Entrinsic Health Solutions, Inc., an innovative health sciences company dedicated to the development and commercialization of amino acid-based medical foods to address critical digestive health, nutrition, and hydration-related health issues, today announced an abstract highlighting the promising results of a pragmatic study of enterade® in reducing cancer therapy-induced gastrointestinal toxicity and dehydration. The abstract has been accepted for a scientific poster presentation at the Multinational Association of Supportive Care in Cancer (MASCC) conference to be held from June 22-24, 2017, in Washington DC.
“This study indicates that our Amino Acid Coupled Transport (A2CT) technology reduces many of the symptoms that arise from cancer therapy-induced gastrointestinal toxicity and dehydration. As anticipated, the results support enterade® as a first-in-class remedy for those who are experiencing side effects from the treatment of cancer. Moving forward, we are confident that enterade® will be the solution to a problem that many patients, healthcare providers, caregivers, and loved ones have been endlessly trying to address,” said Stephen J Gatto, Chairman & CEO of Entrinsic Health Solutions.